Sangamo acquires biotech company for $84m
25-07-2018
Gilead follows Kite acquisition with $567m buy
12-12-2017
Kite accused of infringing Juno’s cancer immunotherapy
05-09-2017
posteriori / iStockphoto.com
Kite Pharma has entered into a collaboration with Sangamo Therapeutics that will see the companies develop next-generation engineered cell therapies to treat cancer.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Sangamo Therapeutics, Kite Pharma, Gilead, cancer, oncology, partnership, collaboration, cell therapies
